I found this and thought it had enough interesting information to post. It gives a little insight into the way effexor works. I am concerned about having more noradrenaline as I am already jittery before I go to sleep. Also it seems that this can cause insomnia which I suffer badly from already. The other point of interest is that although Cymbalta works at low amounts as an SNRI, it seems that effexor works as an SSRI at low amounts and you have to increase it to get the SNRI effect. Does that mean that at low doses we just get the serotonin effects and not the noradrenaline?
Christine
eMedExpert Home > Compare Drugs > Antidepressants Effexor vs. Cymbalta
Antidepressants Comparison: Effexor versus Cymbalta
Serotonin norepinephrine reuptake inhibitors (SNRIs) - new class of antidepressants
Mechanism of action
Absorption
Indications and uses
Off-label (investigational) uses
Adverse reactions and side effects
Brief comparison table
References
SNRIs - new class of antidepressants
Serotonin norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant used to treat depression and other affective disorders. SNRIs were developed more recently than SSRIs and currently there are only two medications in this class approved by the FDA for use: venlafaxine (brand name: Effexor) and duloxetine (brand name Cymbalta). These new drugs, because of their specificity for the serotonin and norepinephrine reuptake proteins, lack most of the adverse side effects of tricyclic antidepressants and monoamine oxidase inhibitors.
Venlafaxine HCl is the first and most commonly used SNRI. Venlafaxine was first introduced by Wyeth Pharmaceuticals in 1993, and marketed under the trade name Effexor.
Duloxetine HCl, manufactured by Eli Lilly, is the newest antidepressant on the market. It was approved by the FDA and released on the market in August 2004.
SNRIs have the ability to affect two neurotransmitters - serotonin and norepinephrine. Clinical studies have shown that the SNRIs are generally quicker acting and more effective in treating severe major depressive disorder, treatment-resistant depression, and depressive symptom remission than SSRI antidepressants, and tricyclic antidepressants.
Comparative studies with SNRIs antidepressants are limited. Currently there is not enough information to firmly recommend any one of these antidepressants over another and selection of antidepressant therapy should be done on an individual basis. Drugs may work differently for different people. What is effective for some may not be effective for others. This article provide some comparative data based on the analysis of medication prescribing information and studies.
Mechanism of action
When serotonin and noradrenaline are released from nerve cells in the brain they act to lighten mood. When they are reabsorbed into the nerve cells, they no longer have an effect on mood. It is thought that when depression occurs, there may be a decreased amount of serotonin and noradrenaline released from nerve cells in the brain.
SNRI antidepressants work by preventing serotonin and noradrenaline from being reabsorbed back into the nerve cells in the brain. This helps prolong the “mood lightening” effect of any released serotonin and noradrenaline. In this way SNRIs help relieve depression. It may take between two to four weeks for the benefits of these medicines.
Effexor XR has the flexibility of being an SSRI at lower doses and an SNRI at higher doses. Cymbalta differs from Effexor in that it is comparatively more noradrenergic.
Cymbalta is also used to treat nerve pain in the feet, legs or hands that is due to nerve damage caused by poorly controlled diabetes. Cymbalta is thought to enhance the nerve signals within the central nervous sytem that naturally inhibit pain.
Absorption
Food does not affect the bioavailability of Effexor or its active metabolite, ODV (O-desmethylvenlafaxine). Time of administration (AM vs PM) did not affect the pharmacokinetics of venlafaxine and ODV from the 75 mg Effexor XR capsule.
Food does not affect the maximal plasma concentrations of Cymbalta, but delays the time to reach peak concentration by approximately 4 hours (from 6 to 10 hours) and it marginally decreases the extent of absorption by about 10%. There is a 3-hour delay in absorption and a one-third increase in apparent clearance of duloxetine after an evening dose as compared to a morning dose.
The bioavailability of Cymbalta appears to be reduced by about one-third in smokers. However, dosage modifications are not considered necessary. The bioavailability of Effexor is not affected by smoking.
Indications and uses
Effexor XR is indicated for the treatment of:
Major Depressive Disorder
Generalized Anxiety Disorder
Social Anxiety Disorder
Cymbalta is indicated for the treatment of:
Major Depressive Disorder
Diabetic Peripheral Neuropathic Pain
The extended-release formulation of Effexor has been approved for the treatment of generalized anxiety disorder and social anxiety disorder; however, these are not labeled indications for Cymbalta. Shortly after duloxetine was approved for the treatment of depression, FDA approved its use for the management of neuropathic pain associated with diabetic peripheral neuropathy. It is the first drug to be approved for this indication, although tricyclic antidepressants (e.g., amitriptyline) and gabapentin have been used off-label for this problem. Duloxetine is also being evaluated in the treatment of stress urinary incontinence (officially approved in Europe for this problem), generalized anxiety disorder, and fibromyalgia, but these are not labeled indications at the present time.
Off-label (investigational) uses
Many doctors are starting to prescribe Effexor “off-label” for the treatment of diabetic neuropathy (in a similar manner to Cymbalta) and migraine prophylaxis (in some people, however, Effexor can exacerbate or cause migraines). Studies have shown Effexor effectiveness for these conditions. It has also been found to reduce the severity of ‘hot-flashes’ in menopausal women. Effexor is also prescribed for off-label uses such as chronic fatigue syndrome, and obsessive-compulsive disorder (OCD).
At present, Cymbalta is not approved for treating bipolar depression, but is being prescribed to people with bipolar disorder as an off-label use. Patients who have experienced mania should be monitored carefully when taking this medication.
There are more controlled studies with Cymbalta showing benefit for all kinds of pain than any other antidepressant. In clinical trials, Cymbalta 60 mg once daily demonstrated efficacy in painful physical symptoms associated with depression. Cymbalta is being studied for the treatment of stress urinary incontinence, which may also respond to treatment with both serotonin and norepinephrine.
Cymbalta is also showing promise for the treatment of fibromyalgia symptoms. In randomized, controlled, 12-week trial, duloxetine was an effective and safe treatment for many of the symptoms associated with fibromyalgia in subjects with or without major depressive disorder, particularly for women, who had significant improvement across most outcome measures.